Back to search

Peptide record

TPDB92102

Dermaseptin - B2 Antibacterial Anticancer Antifungal Antiparasitic Toxicity standard
33 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB92102
Dermaseptin - B2
Antibacterial Anticancer Antifungal Antiparasitic Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF AFP-GFuse Antifungipept CAFPdb dbAMP 3.0 ToxinPred 3.0
standard
No
A 33-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
C-terminal: Amidation
Sequence
GLWSKIKEVGKEAAKAAAKAAGKAALGAVSEAV-NH2
Physicochemical Analysis
C142H242N40O42
RNDCQHMFPTY
A
3181.73
10.27
6
3
18
+3
7.36
0.197
95.15
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
5500
172.86
2
Residue Composition
number
11
A
0
R
0
N
0
D
0
C
3
E
0
Q
4
G
0
H
1
I
2
L
6
K
0
M
0
F
0
P
2
S
0
T
1
W
0
Y
3
V
Amino Acid Distribution
A: 11 R: 0 N: 0 D: 0 C: 0 E: 3 Q: 0 G: 4 H: 0 I: 1 L: 2 K: 6 M: 0 F: 0 P: 0 S: 2 T: 0 W: 1 Y: 0 V: 3
Chemical Descriptors
33
C142H242N40O42
3181.73
10.27
+3
7.36
0.197
Amidation
L
Linear
Free
Antimicrobial
Phyllomedusa bicolor
Evidence Records 16 records
Evidence 1 Activity

Activity

GI50
GI50 > 10 µM
Anticancer
10 µM

Target

Brain Tumor
U-87-MG
Brain

Assay & Model

Crystal Violet assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2017

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation. dbAMP 3.0 classified as Anticancer under the disease-associated peptide function classes.
Evidence 2 Activity

Activity

GI50
GI50 > 10 µM
Anticancer
10 µM

Target

Brain Tumor
U-138-MG
Brain

Assay & Model

Crystal Violet assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2017
Evidence 3 Activity

Activity

GI50
GI50 > 10 µM
Anticancer
10 µM

Target

Brain Tumor
U-373-MG
Brain

Assay & Model

Crystal Violet assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2017
Evidence 4 Activity

Activity

GI50
GI50 > 10 µM
Anticancer
10 µM

Target

Breast Cancer
MDA-MB-231
Breast

Assay & Model

Crystal Violet assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2017
Evidence 5 Activity

Activity

GI50
GI50 > 10 µM
Anticancer
10 µM

Target

Breast Cancer
BT-474
Breast

Assay & Model

Crystal Violet assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2017
Evidence 6 Activity

Activity

GI50
GI50 > 10 µM
Anticancer
10 µM

Target

Breast Cancer
MDA-MB-453
Breast

Assay & Model

Crystal Violet assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2017
Evidence 7 Activity

Activity

GI50
GI50 > 10 µM
Anticancer
10 µM

Target

Pancreatic Cancer
PANC-1
Pancreas

Assay & Model

Crystal Violet assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2017
Evidence 8 Activity

Activity

GI50
GI50 = 2.31 ± 0.41 µM
Anticancer
2.31

Target

Pancreatic Cancer
BxPC-3
Pancreas

Assay & Model

Crystal Violet assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2017
Evidence 9 Activity

Activity

GI50
GI50 = 7.91 ± 1.40 µM
Anticancer
7.91

Target

Pancreatic Cancer
MIA PaCa-2
Pancreas

Assay & Model

Crystal Violet assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2017
Evidence 10 Activity

Activity

GI50
GI50 = 5.08 ± 0.72 µM
Anticancer
5.08

Target

Skin Cancer
HT-144
Skin

Assay & Model

Crystal Violet assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2017
Evidence 11 Activity

Activity

GI50
GI50 > 10 µM
Anticancer
10 µM

Target

Skin Cancer
SK-Mel-28
Skin

Assay & Model

Crystal Violet assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2017
Evidence 12 Activity

Activity

GI50
GI50 > 10 µM
Anticancer
10 µM

Target

Skin Cancer
A-375
Skin

Assay & Model

Crystal Violet assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2017
Evidence 13 Activity

Activity

GI50
GI50 = 0.71 ± 0.55 µM
Anticancer
0.71

Target

Prostate Cancer
DU-145
Prostate

Assay & Model

Crystal Violet assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2017
Evidence 14 Activity

Activity

GI50
GI50 = 2.17 ± 0.48 µM
Anticancer
2.17

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

Crystal Violet assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2017
Evidence 15 Activity

Activity

GI50
GI50 = 2.65 ± 1.09 µM
Anticancer
2.65

Target

Prostate Cancer
LNCaP
Prostate

Assay & Model

Crystal Violet assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2017
Evidence 16 Activity

Activity

100% cytotoxicity at 2.5 µM
Anticancer

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

LDH leakage assay
3-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2017